‘Toxic' claim against supplement giant
Dominic Noonan-O'Keeffe began taking Blackmores supplements in May 2023 to support his health, ahead of the birth of his first child.
Unaware the magnesium product contained potentially 'toxic' levels of vitamin B6, he claims he soon developed severe symptoms – including fatigue, headaches, muscle spasms, heart palpitations, and loss of sensation, according to Polaris lawyers.
Doctors later diagnosed him with neuropathy linked to excessive B6 intake.
Despite stopping in early 2024, Mr Noonan-O'Keeffe claims he continues to suffer daily from nerve pain and other symptoms.
Polaris Lawyers – who are representing Mr Noonan-O'Keeffe, the lead plaintiff in the potential class-action – allege they later discovered the magnesium product contained about 29 times the recommended daily intake of vitamin B6. Mr Noonan-O'Keeffe claims he suffered lasting health impacts after taking Blackmores Magnesium+. Supplied Credit: Supplied
Polaris Lawyers is now investigating a proposed class action against Blackmores for the excessive B6 levels in their vitamin supplements.
'It's alarming to walk down the vitamin aisle of any chemist in Australia and see vitamin supplements containing levels of B6 which are far and above the recommended daily intake,' Polaris Lawyers Founder and Principal Nick Mann said.
'What happened to Dominic is tragic, but he is not alone – we are aware of reports that excessive levels of B6 in over-the-counter supplements may have caused lasting injuries to hundreds of Australians.
'Polaris Lawyers is currently investigating a class action on behalf of anyone who has suffered injuries as a result of excessive levels of B6 as a result of taking Blackmores vitamin supplements.' Blackmores is one of the country's biggest supplement providers. Supplied Credit: Supplied
In an interim decision report released in June, the TGA acknowledged no clear consensus on a safe vitamin B6 level that fully prevents peripheral neuropathy.
The decision proposed rescheduling products containing over 50mg per day as 'Pharmacist Only Medicines.'
A Blackmores spokesperson said they were aware of the TGA's proposed changes.
'At Blackmores, we are committed to the highest standards of product quality and consumer safety. All our products, including those containing Vitamin B6, are developed in strict accordance with the regulatory requirements of the Therapeutic Goods Administration (TGA),' the spokesperson said.
'This includes compliance with maximum permitted daily doses and the inclusion of mandated warning statements.
'We acknowledge the interim decision issued by the TGA and we will ensure full compliance with its final determination.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
10 hours ago
- AU Financial Review
World-leading MDMA production kicks off in Australia
Safe, domestically produced MDMA might be the dream for Australian ravers, but it is now a reality for people with treatment-resistant post-traumatic stress disorder after Melbourne-based psychedelics manufacturer Cortexa finished its first production run of 10,000 capsules. In an Australian first, Cortexa has synthesised the world's largest single batch of high-quality therapeutic MDMA, an undertaking two years in the making and produced under high-level security.
ABC News
10 hours ago
- ABC News
What's behind a spike in adverse event reports for Vyvanse, Australia's biggest ADHD drug?
Australia's pharmaceuticals watchdog is investigating a spike in adverse event reports for Vyvanse, the country's most commonly prescribed ADHD medication. The increase coincides with a leap in prescriptions for ADHD as well as a growing focus on the effectiveness of treatments like Vyvanse on social media. There were 320 adverse event reports relating to Vyvanse — or lisdexamfetamine dimesilate — to the Database of Adverse Event Notifications (DAEN) in the first six months of the year, compared to nine reports in the six months before. The most common adverse events reported were ineffectiveness, anxiety, product labelling issues, therapeutic response decreases and insomnia. The DAEN notes inclusion of an event in the database does not confirm it has been caused by the medication. The World Health Organization's equivalent global database for reporting adverse medicine events has also seen an uptick in reports relating to the active ingredient of Vyvanse, lisdexamfetamine. ADHD is characterised by inattention, hyperactivity and impulsivity. According to a Royal Australian and New Zealand College of Psychiatrists (RANZCP) spokesperson, stimulants, like Vyvanse and Ritalin, appear to normalise some of the brain's main neurotransmitter systems, allowing better regulation of parts of the brain involved in executive function, particularly the frontal lobe. The TGA said its investigations included ongoing independent testing of Vyvanse through TGA laboratories, and that it did not comment on open investigations. "This investigation is the result of a recent increase in adverse event notifications relating to concerns about quality, safety, and reduced effectiveness," a spokesperson said. "Any regulatory actions that arise will be communicated." The TGA also confirmed it had seen an increase in adverse events relating to ADHD-prescribed stimulants more generally, with 754 events registered for the most common drugs — methylphenidate, dexamphetamine and lisdexamfetamine — between January 2015 and June 2025. Only Vyvanse's was significant enough to constitute a safety signal, which is triggered when information suggests a possible causal relationship between adverse events and a drug. "It should be noted that increased usage of a medicine would normally be expected to result in a rise in the number of adverse event reports," the spokesperson said. "Similarly, an uptick in social media commentary would also stimulate reporting." Vyvanse prescriptions almost doubled from 958,831 in 2022 to more than 1.78 million in 2024, according to the Pharmaceutical Benefits Scheme (PBS). RANZCP spokesperson Dr Karuppiah Jagadheesan said an uptick in social media commentary may be contributing to adverse event reporting. Google Trends data shows how much public interest there has been in ADHD and Vyvanse in Australia in recent times, with search volumes and interest in these two search terms both increasing. There are dozens of Reddit threads discussing Vyvanse side effects and effectiveness, and ADHD influencers, whose content ranges from genuine advice to memes, regularly bring the subject up, speaking about their own negative experiences, and encouraging followers to report theirs. Some influencers with tens of thousands of followers have made theories about Vyvanse central to their content. "Social media is very powerful, and certainly there is an element of a shared mindset, and particularly things that are negative can be spread very quickly," Dr Jagadheesan said. Dr Jagadheesan said almost all medications had side effects, and users of Vyvanse should not panic, with adverse events reported by a small percentage of users. He said users should keep taking the medication if it was working for them. "If it's not working adequately or it's wearing off quickly or there are side effects, then they need to talk to their treating doctors, psychiatrist, or GP," he said. He said the RANZCP's committee on ADHD had questioned the effectiveness of Vyvanse at current dosages for some patients, and this may be why ineffectiveness was the most common issue reported to the DAEN. "Sometimes when it doesn't agree with a person it can create side effects like agitation, or even feeling depressed," he said. He said some patients with comorbidities risked mania or psychosis, particularly if they took more than prescribed. Australasian ADHD Professionals Association (AADPA) vice president Dr Sarahn Lovett said the side effects reported for Vyvanse were normal for all stimulants, and she believed a labelling issue on Vyvanse packaging earlier this year had likely contributed to users reporting side effects. The TGA confirmed it previously flagged issues with typos on the drug's packaging, including packaging misspelling "pharmaceutivals", which should have read "pharmaceuticals", and incorrectly pluralising a word so packaging read "each capsules contain". However, the TGA said there were no compliance signals under investigation for the facilities used in manufacturing Vyvanse. Dr Lovett said if Vyvanse was working for a patient, there was no reason to stop taking it, while if it was causing side effects or proving ineffective, users should have a conversation with their prescriber. "The good thing about stimulant medication, however, is that you can stop and start it, so there is no danger to stopping a stimulant — it's just you will no longer be treating your ADHD." Royal Australian College of General Practitioners (RACGP) ADHD spokesperson Tim Jones said the issues went beyond one medication, and adverse event reports aligned with the "pretty astronomical" increase in prescriptions of ADHD stimulants. He said his colleagues in public psychiatry were reporting more mental health admissions related to prescribed stimulants, often triggered by episodes of psychosis, anxiety, and insomnia. "It's something that's certainly entering into serious territory for side effects," Dr Jones said. He said adverse events appear more prevalent among people with complex mental health issues who might have also had an ADHD diagnosis and been started on stimulants. "I think it's a wakeup call to the general safety of stimulants," Dr Jones said. "We do have to have high-quality, balanced discussions with people considering stimulant medications about the relevant positive effects, but also the risk of side effects, because while not common, they are not uncommon either." ADHD Foundation director Christopher Ouizeman said the foundation's helpline had not registered an uptick complaints about Vyvanse. Vyvanse is supplied by Takeda Pharmaceuticals Australia Pty Ltd, and was in the news in early 2024 as Australia suffered months-long shortages of the drug. A Takeda spokesperson said manufacture of Vyvanse was in line with Australia's Therapeutics Goods Act, and strict quality controls were in place. There has been speculation online adverse events began after manufacturing moved to Germany in early 2024. The Takeda spokesperson said the move took place to support increased demand and "there have been no changes to the formulation". Takeda said labelling errors did not impact the quality of the medication.
The Australian
12 hours ago
- The Australian
CMG enters mobility market as joint health interest accelerates
CMG launches UC-II, a collagen-based supplement for joint mobility Product targets knee pain and stiffness with low-dose, once-daily format Joint health market expanding alongside Australia's ageing population Special Report: Joint pain has become a major focus for Australia's booming complementary medicines industry, now worth more than $6.4 billion a year. As the population ages and demand for non-surgical mobility solutions grows, a number of ASX-listed companies are positioning for growth in the space. Among them are Vita Life Sciences (ASX:VLS), EZZ Life Science (ASX:EZZ), Star Combo Pharma (ASX:S66) and McPhersons (ASX:MCP). While each has its own strategy, the common thread is clear: consumers are spending more on supplements that promise functional outcomes like pain relief, energy support and healthy ageing. Now, Complementary Medicines Group (CMG) is entering the conversation with a new product focused on knees - the part of the body most often linked with mobility decline. Called UC-II, the once-daily capsule contains undenatured type II collagen and has been shown in clinical studies to support joint function, reduce stiffness and improve walking ability in people experiencing mild osteoarthritis or wear-and-tear from an active lifestyle. Dr Brad McEwen PhD, a researcher at CMG, said the formula offered something new for consumers. 'UC-II works by helping the immune system recognise inflammation in the joint and respond appropriately. It targets the underlying cause, not just the symptoms,' he said. 'What makes it unique is the dose. You only need 40 milligrams per day. It is an efficient, well-tolerated alternative to high-dose glucosamine or chondroitin.' Market conditions are shifting Mobility health has emerged as one of the most promising supplement categories in Australia, particularly among people aged 35 and over. More than half of Australian adults use complementary medicines and nearly three in four households report keeping supplements on hand. Pill fatigue, rising interest in preventive health and a growing appetite for clinically validated products are all shaping how consumers choose what to buy. CMG's UC-II has been formulated to address those trends, with supporting evidence from more than a dozen clinical trials. In a six-month study, participants taking UC-II reported improved joint flexibility and reduced pain when climbing stairs, standing upright and walking longer distances. The product is now available through Go Vita stores nationally and is sold under several trusted brand names. Quality and compliance remain key Australia is considered one of the most tightly regulated markets in the world for complementary medicines. All products must be listed on the Australian Register of Therapeutic Goods and adhere to standards set by the Therapeutic Goods Administration. That quality assurance is also a key reason why exports have climbed to more than $1.2 billion per year. For CMG, the goal is not just to enter the category, but to lead with a formulation that is simple, proven and well-positioned for both domestic and export markets. With continued growth in the broader sector and increasing interest in mobility-focused products, the company is hoping UC-II will meet a real and growing need. This article was developed in collaboration with Complementary Medicines Group, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
